Synonym
MMI-166; MMI 166; MMI166
IUPAC/Chemical Name
D-Tryptophan, N-((4-(2-phenyl-2H-tetrazol-5-yl)phenyl)sulfonyl)-
InChi Key
NLABJQQLMHAJIL-JOCHJYFZSA-N
InChi Code
InChI=1S/C24H20N6O4S/c31-24(32)22(14-17-15-25-21-9-5-4-8-20(17)21)28-35(33,34)19-12-10-16(11-13-19)23-26-29-30(27-23)18-6-2-1-3-7-18/h1-13,15,22,25,28H,14H2,(H,31,32)/t22-/m1/s1
SMILES Code
OC(=O)[C@@H](Cc1c[nH]c2ccccc12)NS(=O)(=O)c3ccc(cc3)c4nnn(n4)c5ccccc5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
488.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Gao CC, Gong BG, Wu JB, Cheng PG, Xu HY, Song DK, Li F. MMI-166, a selective matrix metalloproteinase inhibitor, promotes apoptosis in human pancreatic cancer. Med Oncol. 2015 Jan;32(1):418. doi: 10.1007/s12032-014-0418-5. Epub 2014 Dec 4. PMID: 25471789.
2. Nakabayashi H, Yawata T, Shimizu K. Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer. 2010 Jun 29;10:339. doi: 10.1186/1471-2407-10-339. PMID: 20587068; PMCID: PMC2909207.
3. Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett. 2002 Apr 25;178(2):151-9. doi: 10.1016/s0304-3835(01)00837-0. PMID: 11867199.
4.Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Oba K, Kaneko T, Syouji T, Igarashi A, Nakamura S. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res. 2001 Jun;92(6):688-95. doi: 10.1111/j.1349-7006.2001.tb01149.x. PMID: 11429059; PMCID: PMC5926761.
5. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, Kaneko T, Shouji T, Igarashi A, Nakamura S. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett. 2002 Jan 10;175(1):45-51. doi: 10.1016/s0304-3835(01)00726-1. PMID: 11734335.
